Previous 10 | Next 10 |
- Pivotal results expected in March/April 2020 - - Details of the program to be reviewed at company’s Investor Day today in NY - REDWOOD CITY, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today anno...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch to s...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
-Management to Review Late Stage Development, NDA-readiness and Commercial Opportunity of Serlopitant- -Discussion to Feature two Prominent Key Opinion Leaders Well Versed in the Unmet Needs of the Prurigo Nodularis and Chronic Pruritus of Unknown Origin Patient Populations- REDWOO...
Menlo Therapeutics (NASDAQ: MNLO ) initiated with Buy rating and $11 (140% upside) price target at H.C. Wainwright. More news on: Menlo Therapeutics Inc., Dynavax Technologies Corporation, UnitedHealth Group Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...
REDWOOD CITY, Calif., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, presented results from its successful Phase 2 clinical trial of serlopitant for the treatment of pruritis in patients with psoriasis in an oral presentatio...
REDWOOD CITY, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steven Basta, chief executive officer of Menlo Therape...
- Results expected in Q1 2020 - REDWOOD CITY, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced that it has completed patient enrollment in its Phase 2 clinical trial evaluating the safety and effi...
Quick Take BELLUS Health ( BLU ) has filed to raise gross proceeds of $60 million from a U.S. IPO, according to an F-10 registration statement . The firm is developing therapeutics for chronic cough and other hypersensitization disorders. BLU is in the middle of Phase 2 trials for its l...
REDWOOD CITY, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Kristine Ball, chief financial officer of Menlo Therape...
News, Short Squeeze, Breakout and More Instantly...
BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22 nd Annual Global Investment Confe...
BRIDGEWATER, N.J. , Sept. 8, 2020 /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from "MNLO" to "...
Company will commence trading under new ticker “VYNE” on September 8, 2020 Company to ring Nasdaq Closing Bell on September 8 BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”...